Second, the off-label adoption pattern that the longevity reframing will inevitably accelerate is going to produce the next wave of monitoring, dosing, and selection problems, patients without obesity or diabetes do not have the diagnostic anchors (BMI, A1c, insulin resistance markers) that frame the on-label conversation, and the clinical infrastructure for managing GLP-1 therapy in metabolically healthy users is, charitably described, thin
Standardizing assay conditions simplified comparisons across multiple experimental batches
Only the specific numbers will change
Patients enjoy both weight-dependent decrease in blood glucose, in addition to the benefits of decreased weight and direct cardiovascular advantages. The research was funded by Novo Nordisk, the manufacturers of Ozempic
Renal and Hepatic Impairment: Does Organ Function Change Exposure
Concerns around side effects, long-term safety, cost and whether medication feels necessary in the first place all play their part in informing how people feel about starting weight loss treatments